Skip to main content

Breast Cancer

Zoledronic Acid Prolongs Survival Only in Postmenopausal Breast Cancer Patients

By Daniel M. Keller

Breast Cancer, In the News

SAN ANTONIO—In a trial involving women with stage II/III breast cancer (N = 3360), adding zoledronic acid (ZA) to standard adjuvant chemotherapy did not prolong overall survival (OS) or disease-free survival (DFS) after a median follow-up of 59 months, contrary to some previous reports. Read More ›

Daniel M. Keller

Reports from the European Breast Cancer Conference and the European Association of Urology Congress

CEP17 Breast Cancer Tumors Are More Likely to Respond to Anthracyclines

BARCELONA—Breast cancer patients with the chromosome enumeration probe 17 (CEP17) alpha satellite abnormality are more likely to have good outcomes from chemotherapy involving anthracycline antibiotics than women without the abnormality, according to new data released at the Seventh European Breast Cancer Conference.

Trastuzumab Best Given Along with Chemotherapy

April 2010 Vol 3, No 2

For women with human epidermal growth factor receptor type 2 (HER2)-positive early breast cancer, delaying trastuzumab until chemotherapy is completed may impair outcomes, according to findings from the landmark N9831 trial. The findings were presented by Edith Perez, MD, director of the Breast Cancer Program at the Mayo Clinic, Jacksonville, Florida.

To Protect Bone, Denosumab Outperforms Zoledronic Acid in Breast Cancer Patients

April 2010 Vol 3, No 2

For the prevention of skeletal-related events (SREs) in breast cancer patients with bone metastasis, denosumab proved superior to zoledronic acid (ZA) in a head-to-head randomized comparison conducted in 2048 women.

Advances in Breast Surgery

By Laura Dominici, MD; Mehra Golshan, MD

The discipline of breast surgery, like many specialties, has moved toward a minimally invasive approach to local therapy. Radical surgery had previously been the standard; however, surgical approaches continue to evolve as we gather more data about the oncologic safety of less invasive procedures. In addition, we are placing more emphasis on targeted therapy, and surgery is an integrated portion of patient care. Read More ›

Laura Dominici, MD, Mehra Golshan, MD

Page 12 of 12